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HIV/TB CO-INFECTION:THE CHALLENGES




Tuberculosis (TB) is a major cause of morbidity and mortality worldwide.  Each year, there 
are eight million new Mycobacterium tuberculosis complex (MTB) infections and three 
million TB-related deaths.  The catastrophic effects of TB are borne disproportionately 
among the most vulnerable.  The HIV pandemic has further increased the burden so 
that the risk of TB reactivation from latency is five to 15 percent in HIV/TB coinfection.  
Tuberculosis reactivation fuels further primary infections, creating a vicious cycle of 
increasing infection, disease, and deaths.  In addition, drug-resistant TB exacerbates 
this increasingly common problem.
INTROduCTION
Tuberculosis is one of the leading causes of morbidity 
and mortality in the world.  Each year approximately 
eight million people acquire MTB infection, and 
three million people  die from the disease. But, as is 
common with most infectious diseases, the poorest 
and most vulnerable populations pay the highest toll. 
The HIV pandemic has enlarged the population of 
susceptible individuals, resulting  in a net increase 
in morbidity and mortality rates.  Even before the 
AIDS pandemic, an estimated 50 percent of adults 
had MTB infection in sub-Saharan Africa, with an 
incidence of about 200 per 100,000 people.  Nationwide 
notification rates and hospital-based studies suggest 
that the incidence of TB has more than doubled since 
the early 1980s in those countries where the rates of 
HIV are highest (4).
 In 1997, global prevalence of MTB infection was 
32 percent, accounting for 1.86 billion people.  Eighty 
percent of all incident TB cases were found in 22 
countries, with more than half the cases occurring in 
five Southest Asian countries.  Nine of ten countries 
with the highest incidence rates were in Africa. 
Prevalence of MTB/HIV co-infection worldwide 
was 0.18 percent, and 640,000 incident TB cases (8%) 
had HIV infection.  The global burden of TB remains 
enormous because of inadequate TB control in sub-
Saharan Africa, and the high rates of MTB/HIV co-
infection in African countries.
 About a third of the 40 million people living with 
HIV are co-infected with M-tuberculosis.  HIV is the 
most powerful known risk factor for reactivation of 
latent MTB infection to active TB disease, in which 
the annual risk of developing TB disease from MTB 
infection ranges from five to 15 percent.  HIV-infected 
people who become newly infected by MTB carry 
higher risk of progression to active TB.  Tuberculosis 
is the leading cause of death among people with 
HIV infection, accounting for a third of AIDS-related 
deaths worldwide.  In addition, there is a concomitant 
emergence of multi-drug-resistant (MDR) strains of 
MTB to isoniazid (INH) and at least rifampin (RIF), 
among other anti-tuberculous agents.
 HIV and TB are also intricately linked to 
malnutrition, unemployment, alcoholism, drug 
abuse, poverty and homelessness.  The direct and 
indirect costs of  illness due to TB and HIV are 
enormous, estimated to be more than 30 per cent of 
the annual household income in developing countries 
and have a catastrophic impact on the economy in 
the developing world (10).  Thus, co-infection with 
HIV and TB (HIV-TB) is not only a medical malady, 
but a social and an economic disaster and is aptly 
described as the “cursed duet.”
 In contrast to western countries, where 
Pneumocystis jiroveci pneumonia was the most 
common AIDS-defining illness, in developing 
countries TB is the most common life-threatening 
opportunistic infection (OI) in patients with HIV/
AIDS with about 25 to 65 per cent of patients with 
HIV/AIDS having tuberculosis of any organ (11).  
CHALLENGES TO HEALTH CARE WORKER 
IN TB INFECTION
The combination of an increasing prevalence of TB, 
HIV, and multi-drug resistant tuberculosis (MDR-
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TB) has led to increased hospitalisation of patients 
with infectious TB and to increased risk for MTB 
transmission to HCWs, other patients, and visitors. 
There have been two adverse effects: the rising 
prevalence of MDR-TB involved in outbreaks, and 
the high rates of morbidity and mortality among 
immunocompromised people, particularly those 
with AIDS.
 Several factors influence the transmission of TB, 
including delayed or failed diagnosis in the source 
case; closed, re-circulating air systems with minimal 
fresh air ventilation; exposure of highly vulnerable 
individuals; and reduced efficacy or failure of 
chemotherapy from drug resistance among source 
cases.
 Human immunodeficiency virus (HIV) infection 
is a potent risk factor for tuverculosis (TB).  Not only 
does HIV increase the risk of reactivating latent 
Mycobacterium tuberculosis (MTB) infection, it also 
increases the risk of rapid TB progression soon after 
infection or reinfection with MTB.  In persons infected 
with MTB only, the lifetime risk of developing TB 
ranges between 10 and 20%.  In persons co-infected 
with MTBand HIV, however, the annual risk can 
exceed 10%.  The TB burden in countries with a 
generalised HIV epidemic has therefore increased 
rapidly over the past decade, especially in the severely 
affected countries of Eastern and Southern Africa.  
 It is possible that, in addition to increasing 
individual susceptibility to TB following MTB 
infection, the increased burden of HIV-associated TB 
cases also increases MTB transmission rates at the 
community level, threatening the health and survival 
of HIV-negative individuals as well. In several 
countries HIV has been associated with epidemic 
outbreaks of TB, and many of the reported outbreaks 
involved multidrug-resistant strains responding 
poorly to standard therapy.
CLINICAL, RAdIOGRAPHIC ANd 
PATHOLOGIC FINdINGS
Unlike other opportunistic infections which occur 
at CD4+ counts below 200/mm, active TB occurs 
throughout the course of HIV disease. Clinical 
presentation of TB in HIV-infected individuals 
depends on the level of immunosuppression resulting 
from HIV infection.  In patients with relatively 
intact immune function (CD4+ count > 200/mm), 
pulmonary TB (PTB) is more frequently seen than 
extrapulmonary TB (EPTB). In these patients, chest 
radiographic findings include upper  lobe infiltrates 
and cavitation, similar to those in HIV-negative 
individuals with PTB. Sputum smears are often 
positive for acid-fast bacilli (AFB) in these patients. 
As immunosuppression progresses, EPTB  become 
increasingly common. In contrast to HIV-negative 
patients with EPTB, the disease is often disseminated 
involving two or more non-contiguous organs 
concomitantly, in patients with HIV/AIDS
 In developing countries, EPTB is the most 
common cause of pyrexia of unknown origin (PUO)
among HIV-infected patients. Common forms of 
extrapulmonry involvement include extrathoracic 
lymph node TB, pleural effusion, meningitis and 
abdominal TB. In advanced HIV/AIDS, lymph node 
involvement is characterised by poor granuloma 
formation with abundant AFB, in a background of 
neutrophils and florid necrosis. In contrast to HIV-
negative patients in whom pleural effusion due to 
TB often resolves spontaneously, it is progressive 
and remain culture-positive for M. tuberculosis for 
prolonged period of time in patients with HIV/
AIDS. In addition, pleural fluid shows abundant 
mesothelial cell in these patients, a finding reflecting 
poor inflammatory response due to HIV/AIDS 
(15).
 TB meningitis is accompanied by TB elsewhere 
in the body in most of the patients with HIV-TB and 
the cerebrospinal fluid (CSF) is often acellular; at 
times, CSF may be completely normal both in cellular 
and biochemical characteristics. In patients with 
acellular CSF,meningeal signs may not be evident 
clinically. Apart from these differences intracerebral 
mass lesions are more commonly present in HIV-
infected patients with TB meningitis. Hepatosplenic 
focal lesions an intra-abdominal lymphadaenopathy 
are more common in HIV-infected patients with 
abdominal TB; on the other hand, ascites and omental 
thicknening are less common  when compared to HIV-
negative patients with abdominal TB. In patients with 
advanced HIV/AIDS mycobacteraemia is commonly 
demonstrable Cutaneous lesions appearing as small 
papules or vesiculopapules are more commonly 
found in HIV-infected patients with miliary TB. These 
are called tuberculosis cutis miliaris disseminata, 
tuberculosis cutis acuta generalisata and acute miliary 
tuberculosis of the skin.
 Chest radiographic findings in patients with 
advanced HIV diseases are characterised by frequent 
lower lobe involvement, air-space consolidation 
similar to bacterial pneumonia and absence of 
cavitations sputum smears are seldom positive for 
AFB.
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 Intrathoracic lymphadenopathy is often evident 
in these patients, resembling primary TB, regardless 
of the prior TB exposure status. A miliary pattern 
of involvement is also associated with severe 
immunosuppression. Interestingly, a considerable 
proportion of patients (10 to 20%) with advanced 
immunosuppression may have apparently normal 
looking chest radiographs, yet M. tuberculosis can 
be demonstrated or isolated from their sputum or 
bronchoalveolar lavage fluid. However, computed 
tomography (CT) demonstrates abnormalities such 
as pulmonary nodules tuberculoma and intrathoracic 
lymphadenopathy in these patients.
dIAGNOSIS
Even though it is recommended that all patients 
with active TB should be tested for HIV infection 
compliance with this recommendation is poor even in 
developed nations. Selective HIV testing of TB patients 
is considered unwise because physicians often fail to 
identify the risk factors for HIV transmission.
Diagnosis of TB in HIV/AIDS
Diagnosis of TB in HIV-infected patients is often 
difficult due to several reasons (i) frequently negative 
sputum smear, (ii) atypical radiographic findings. (iii) 
Higher prevalence of EPTB especially at inaccessible 
sites, and (iv) resemblance to other opportunistic 
pulmonary infections (21). However, the diagnosis 
approach to suspected TB in a HIV-infected individual 
is similar to that in immunocompetent patients, 
except that invasive diagnostic procedures are 
more often required to establish the diagnosis. CT 
scan and magnetic resonance imaging (MRI) have 
facilitated the detection and characterisation of occult 
foci of EPTB. Attempts should be directed towards 
arriving at a bacteriological diagnosis, since multiple 
pathogens often coexist, and it is not possible to 
distinguish from atypical mycobacterial infections 
based on clinical and radiological findings alone. 
Peripheral blood cultures need to be performed to 
detect mycobacteraemia.  
 Several molecular diagnostic techniques based 
on detection of M.tuberculosis specific DNA or 
ribosomal RNA sequences by polymerase chain 
reaction (PCR) have been developed in the recent 
past.  However, the appropriate use of these tests 
in the diagnosis of active TB, especially in patients 
with HIV/AIDS need to be defined.  Messenger 
RNA (mRNA)based PCR techniques may be useful 
in assessing the response to treatment and detection 
of mutations in the rpo-B gone might be useful for 
rapid drug susceptibility testing.
TREATMENT OF HIV-TB CO-INFECTION
Availability of highly active anti-retroviral therapy 
(HAART) has significantly improved the outcome 
of HIV/AIDS, in terms of prevention of OIs as 
well as mortality.  Specifically, benefit in terms 
of prevention of TB has been demonstrated in 
South Africa and outcome of patients with HIV-
TB co-infection has improved over the years, 
attributable to improvements in anti-retroviral and 
antituberculosis treatment.  Thus understandably, 
both antituberculosis treatment and HAART are 
indispensable in the management of patients with 
HIV-TB.  However, substantial pharmacokinetic 
interactions occur between the rifamycin component 
of antituberculosis treatment and anti-retroviral 
drugs especially, protease inhibitors (PIs) and non-
nucleoside reverse transcriptase inhibitors (NNRTIs). 
Moreover, short-course antituberculosis regimes used 
in immunocompetent patients are not so well studied 
in the setting of HIV co-infection.
 The key therapeutic principle underlying the 
treatment of HIV-TB are:
(i) treatment of TB always takes precedence over 
treatment of HIV infection
(ii) in patients who are already on HAART, the 
same has to be continued with appropriate 
modi f ica t ions  both  in  HAART and 
antituberculosis treatment, and
 (iii) in patients who are not receiving HAART, the 
need and timing of initiation of HAART have to 
be decided after assessing the short-term risk of 
disease progression and death, based on CD4+ 
count and type of TB, on an individuals basis.
There is no evidence regarding the appropriate 
time for initiating HAART in patients with HIV-
TB. A retrospective study found that in severely 
immunosuppressed patients with HIV-TB, early 
initiation of HAART was associated with reduced 
mortality and disease progression.  British HIV 
Association (BHIVA) recommends that if CD4+ counts 
are >200/mm, HAART can be started after completion 
of anti-tuberculosis treatment, if indicated; if 
CD4+ counts are 100-200/mm, HAART can be started 
after two months of TB and when CD4+ counts are 
<100mm, HAART has to be initiated as soon as 
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possible after starting anti-tuberculosis treatment. 
Guidelines laid by the WHO for use in resource-
limited settings are available (28).
 Of all rifamycins, rifabutin induces hepatic 
cytochrome CYP3A4 the least and is the preferred 
rifamycin for concurrent administration with 
HAART. In such a case, ritonavir and hard-gel 
formulation of saquinavir (PIs) and delaviridine 
(NNRTI) should not be used, dosages of indinavir 
and nelfinavir need to be increased to 1000 mg q8h 
and 1250 mg q12h, respectively and that of rifabutin 
has to be decreased to 150 mg/day, since PIs inhibit 
the metabolism of rifabutin and increase the rate of 
uveitis associated with rifabutine. In resource-limited 
settings where rifabutin is not available, ritonavir 
boosted saquinavir (SQV/r) is the recommended 
PI and efavirenz at increased dosage (800 mg/
day) is the preferred NNRTI to be given along with 
two nucleoside reverse transriptase inhibitors, for 
concurrent administration with rifampicin containing 
anti-tuberculosis regimes.
Principles of anti-tuberculosis treatment in the setting 
of HIV-TB are identical to those for HIV negative adults 
with two exceptions.  In HIV infected patients with TB 
caused by or presumed to be caused by susceptible 
strains of M. tuberculosis DOTS should be initiated 
with isoniazid, rifampicin/ rifabutin, pyrazinamide 
and ethambutol for the first two months followed 
by rifampicin and isoniazid for the subsequent four 
months.  The initial response to six month therapy 
in HIV co-infected TB patients is good and the rate 
of recurrences is also similar to that of HIV-negative 
patients if rifampicin is administered for at least six 
months (31).  However, higher recurrence rates have 
been observed in some studies and were probably 
due to re-infection rather than treatment failure. 
Extended post-treatment isoniazid (INH) therapy 
has been shown to decrease the risk of recurrence in 
patients who had symptomatic HIV disease before 
the diagnosis of TB33.
Adverse drug reactions
HIV-infected patients are more prone to develop 
adverse reactions to anti-tuberculosis drugs and 
need to be carefully monitored.  The risk of adverse 
drug reactions (ADRs) increases with advanced 
immunosuppression and majority of the ADRs occur 
in the first two months of treatment.  These include skin 
rash, usually caused by thiacetazone and sometimes 
by rifamoicin and streptomycin gastrointestinal 
disturbances and drug-induced hepatotoxicity 
among others. Thiacetazone can cause fatal ADRs 
and hence is contraindicated in HIV-infected 
patients.  HIV-infected patients are more prone to 
develop isoniazid-induced peripheral neuropathy 
and all HIV-TB patients receiving isoniazid should 
be given pyridoxine supplementation (10-25 mg/
day). Rifampicin reduces the effectiveness of oral 
contraceptive pills and patients should be advised 
to use other forms of contraception.
Immune reconstitution inflammatory syndromes
Paradoxical reactions, also called immune restoration 
syndromes or immune reconstitution inflammatory 
syndromes (IRIS) have been reported in 32 to 36 
per cent of patients with HIV-TB, within days to 
weeks after the initiation of anti-retroviral treatment. 
At times these can be delayed, occurring after 
several months. Manifestations range from isolated 
instances of fever to increased or initial appearance 
of lymphadenopathy, new or worsening pulmonary 
infiltrates, serositis, cutaneous lesions and new or 
expanding central nervous system mass lesions. 
Consequently, some patients may develop acute 
renal failure or acute respiratory distress syndrome 
(ARDS).  IRIS can be brief or prolonged with multiple 
recurrences.
 These pose a diagnostic problem and have to 
be distinguished from TB treatment failure, and 
other OIs common among HIV-infected patients. 
Recent evidence suggests that CD4+ T-lymphocyte 
percentage and ratio of CD4+ to CD8+ T-lymphocytes, 
rather than CD4 + T-lymphocyte count, were the 
only factors independently associated with IRIS, 
suggesting that unbalanced T-cell response may be 
a key factor in the pathogenesis of IRIS. In general, 
anti-retroviral therapy should not be interrupted if 
IRIS occurs.  Non-steroidal anti-inflammatory drugs 
may provide some relief, but some patients require 
adjunctive corticosteroid administration.
OuTCOME
The mortality of HIV-infected patients with TB is 
comparatively higher than that of HIV-negative 
TB patients. The mortality depends upon the 
type of disease and the degree of underlying 
immunosuppression. In HIV- infected patients with 
TB meningitis, mortality is about 60-70 per cent, 
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despite adequate treatment.  However, with adequate 
anti-tuberculosis therapy, occurrence of TB has been 
found to have no independent effect on mortality in 
hospitalised HIV-infected patients.  Other OIs which 
often go undiagnosed are a common cause of death 
in patients with HIV-TB, especially those dying later 
during anti-tuberculosis treatment.
PREVENTION OF HIV-TB
All newly detected HIV-infected patients should 
undergo a tuberculin skin test and prophylactic 
therapy should be offered to those patients with LTBI 
(induration>5 mm).  Treatment of LTBI substantially 
reduces the risk of developing active TB  in HIV 
infected patients and has also been shown to reduce 
the mortality.  The protection offered lasts for two 
and a half to three years.
 However, in practice, especially in Kenya for 
reasons not well understood, treatment of LTBI is not 
widely offered.  This is partly due to apprehension 
regarding inadvertent monotherapy of active TB 
and therapeutic nihilism on the part of physicians 
regarding the effectiveness of prophylactic treatment 
for fixed duration in a country where TB is endemic. 
Reliably ruling out active TB is likely to prove a 
bottleneck while implementing this strategy as a part 
of national progremme, and operational research if 
urgently required in this aspect in Kenya.
BCG VACCINATION
While persons known to be HIV-infected should 
never be given bacilli Calmette-Guerin (BCG), which 
is a live attenuated vaccine, the WHO advocates that 
routine immunisation of infants should nevertheless 
continue in areas with a high incidence of TB and 
HIV infection.  Prior BCG vaccination offers modest 
protection against all forms of TB, independent of 
HIV status; however, HIV infection nullifies the 
protection offered by BCG against the development 
o EPTB.  This is in contrasts to HIV-negative patients 
in whom BCG vaccination offers maximum protection 
against the development of extrapulmonary TB such 
as meningitis and military TB.
CONCLuSION
The worldwide incident of TB is increasing currently, 
particularly in areas of the southern hemisphere where 
HIV epidemics are devastating because anti-retroviral 
therapies are not available. HIV-infected patients are 
at extremely high risk for progression from latent TB 
to active disease, and unusual clinical manifestations 
of TB should not be ignored in this high-risk group. 
Patients receiving HAART may have significant drug-
drug interactions when rifampicin is used with PIs 
of NNRTIs, and risk developing severe paradoxical 
reactions attributable to immune restoration.  Finally, 
the dramatic extension of anti-TB drug resistance, 
caused partially by the HIV epidemics, as seen 
currently in Southeast Asia, India, sub-Saharan Africa 
and South America, should be taken into account by 
international public health authorities. 
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